Amlodipine Besylate And Atorvastatin Calcium Tablet, Film Coated
Product Images NDC 43598-321

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Amlodipine Besylate And Atorvastatin Calcium (NDC 43598-321). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr. Reddy's Laboratories Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Container1 (Container1)

FDA Label Image

Container10 (Container10)

FDA Label Image

Container11 (Container11)

FDA Label Image

Container2 (Container2)

FDA Label Image

Container3 (Container3)

FDA Label Image

Container4 (Container4)

FDA Label Image

Container5 (Container5)

FDA Label Image

Container6 (Container6)

FDA Label Image

Container7 (Container7)

FDA Label Image

Container8 (Container8)

FDA Label Image

Container9 (Container9)

FDA Label Image

Figure1 (Figure1)

FDA Label Image

Figure2 (Figure2)

FDA Label Image

Figure3 (Figure3)

FDA Label Image

Figure4 (Figure4)

This is a graph that shows the cumulative hazard for Placebo and Atorvastatin over time. The hazard is measured as the likelihood of experiencing the primary endpoint, which is not specified in the given text. The x-axis represents the time to the first primary endpoint over four years of follow-up, while the y-axis represents the cumulative hazard percentage. Atorvastatin has a lower hazard ratio (HR) than Placebo, 0.63, which is statistically significant with a p-value of 0.001.*

FDA Label Image

Figure5 (Figure5)

This appears to be a table showing the percentage of subjects who experienced a cardiovascular event while taking either 10mg or 80mg doses of atorvastatin. The HR (hazard ratio) is also listed as 0.78 with a confidence interval, suggesting that the 80mg dose was more effective in reducing the risk of a cardiovascular event, compared to the 10mg dose. Additionally, a graph displays the time to first major cardiovascular endpoint over the span of four years.*

FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.